P fell nearly 9% on the week to $93.78, yet the data underneath the tape tells a quieter, more constructive story than the price action alone suggests.
The most interesting tension right now is the gap between price and positioning. Everpure gave back a meaningful chunk of its post-earnings surge — the stock had climbed to $108.90 the day of its August 26 print — but short sellers did not use the pullback to rebuild. Short interest continued falling, dropping 12.7% on the week to 2.67% of free float. That is the lightest short position in over a month, and it follows a broader trend: SI has fallen nearly 14% in the past 30 days, with a visible step-change downward around August 25 when roughly 1.3 million borrowed shares were returned to the pool. Bears who pressed the stock ahead of earnings kept retreating even as prices corrected. That is a notable non-confirmation of the dip.
The borrow market reinforces that read. Availability is essentially unconstrained — the ratio of shares available to borrow against shares already borrowed is running near the absolute cap of the data range, meaning lenders have far more supply than shorts have demand. Borrowing cost has also eased, down 41% on the week to just 0.26% annually. Those numbers say the infrastructure for a short campaign is cheap and plentiful. The fact that shorts are still leaving despite that ease is more telling than the raw SI level itself. The options picture adds a wrinkle. The put/call ratio eased slightly from its 52-week high of 0.83 (hit August 31) to 0.82, but remains elevated — running about 1.4 standard deviations above its 20-day mean of 0.73. That is not a fresh directional bet. As the previous note observed, the PCR has been drifting higher for two weeks in a way that looks more like long holders buying downside hedges into a volatile tape than active shorting through the options market. The ORTEX short score has also drifted lower, from 34.4 two weeks ago to 33.3 now — consistent with the broader easing of short-side pressure.
On the Street, the consensus has rarely looked this aligned. Thirteen analysts rate P a Buy against a single Hold, and the analyst rec-diff factor ranks in the 100th percentile of the ORTEX universe — as uniformly bullish as it gets. The flood of target raises following the August 26 earnings print has left the mean target at $130.53, implying roughly 39% upside to Tuesday's close. The most significant individual move was B of A's Wamsi Mohan upgrading to Buy with a $150 target on August 27, a 67% lift from his prior $90 target. JP Morgan's Samik Chatterjee went to $145. Even Barclays, maintaining its lone Equal-Weight hold-out, moved its target from $84 to $110. UBS, the only outright Sell, raised to $80 — still deeply detached from consensus and now looking increasingly isolated. EPS momentum ranks in the 91st percentile on a 30-day basis and 78th on a 90-day basis, supporting the earnings-driven re-rating narrative. Valuation has moved: the PE multiple is around 30x and the price-to-book near 13.7x, both up meaningfully over the past 30 days. Bulls point to forward EPS growth tracking north of 280% year-on-year and revenue expanding at 21%. Bears flag negative operating margins and component cost exposure as reasons the valuation premium could compress quickly if growth stumbles.
Founder John Colgrove remains a notable institutional presence, holding about 3.4% of shares as of mid-August — though that stake has declined from prior levels, with his reported last change showing a reduction of nearly 790,000 shares. The insider data in aggregate is stale (the most recent Form 4 filings are from early January 2026, over 230 days ago), so no fresh read on insider conviction is available from the SEC data. On the passive side, FMR holds 15% and BlackRock 10.4%, both as passive long-term holders filing under 13G rather than the activist 13D framework. No activist presence has been disclosed.
The next earnings event is flagged for September 23. The previous two prints produced a roughly flat-to-down 1-day reaction — a 0.9% drop in June and a 3.5% drop in August — before recovering over the subsequent week. With the stock now trading 14% below its post-earnings high and the consensus target sitting 39% above the tape, the setup heading into the September print is less about whether the thesis is intact and more about whether the multiple can re-expand after a week of mean-reversion selling.
See the live data behind this article on ORTEX.
Open P on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
